Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2185-2191

  Nishimura, Y ^a   Watanabe, J ^b   Jobo, T ^b   Kato, N ^a   Fujisawa, T ^a   Kamata, Y ^a   Kuramoto, Hiroyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell cycle; Cyclin D1; Endometrial adenocarcinoma

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 4444281360     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Motokura T and Arnold A: Cyclins and oncogenesis. Biochim Biophys Acta 1155: 63-78, 1993.
2. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Gene Dev 13: 1501-1512, 1999.
3. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79: 551-555, 1994.
4. Grana X and Reddy EP: Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases(CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors(CKIs). Oncogene 11: 211-219, 1995.
5. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A and Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369: 669-671, 1994.
6. Sicinski P, Donaher JL, Parker SB et al: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630, 1995.
7. Fantl V, Stamp G, Andrews A, Rosewell I and Dickson C: Mice lacking cyclin D1 is small and show defects in eye and mammary gland development. Gene Dev 9: 2364-2372,1995.
8. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M and Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361, 1994.
9. Akiyama N, Tsuruta H, Sasaki H, Sakamoto H, Hamaguchi M, Ohmura Y, Seto M, Ueda R, Hirai H, Yazaki Y et al: Messenger RNA levels of five genes located at chromosome 11q13 in B-cell tumors with chromosome translocation t(11;14)(q13;q32). Cancer Res 54: 377-379, 1994.
10. Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM and Weinstein IB: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 196: 1010-1016, 1993.
11. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu S and Weinstein IB: Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52: 2980-2983, 1992.
12. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G and Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99, 1996.
13. Utsumi T, Yoshimura N, Maruta M, Takeuchi S, Ando J, Mizoguchi Y and Harada N: Correlation of cyclin D1 mRNA levels with clinico-pathological parameters and clinical outcome in human breast carcinomas. Int J Cancer 89: 39-43, 2000.
14. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48: 6-29, 1998.
15. Cauley JA, Gutai JP, Kuller JH, LeDonne D and Powell JG: The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 29: 1120-1131,1989.
16. Jobo T, Tateoka K and Kuramoto H: Study on the long-term follow-up of endometrial hyperplasia. Int J Clin Oncol 1: 163-169, 1996.
17. Ohkawara S, Jobo T, Sato R and Kuramoto H: Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia. Eur J Gynaec Oncol 21: 573-577, 2000.
18. Nikaido T, Li S, Shiozawa T and Fujii S: Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 78: 1248-1253, 1996.
19. Shih H-C, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, Nikaido T and Konishi I: Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 34: 471-478, 2003.
20. Ito K, Sasano H, Yoshida Y, Sato S and Yajima A: Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma. Anticancer Res 18: 1661-1664, 1998.
21. FIGO news. Int J Gynecol Obstet 28: 189-193, 1989.
22. Bartkova J, Lukas J, Strauss M and Bartek J: Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 172: 237-245, 1994.
23. Lukas J, Pagano M, Staskovic Z, Draetta G and Bartek J: Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumor cell lines. Oncogene 9: 707-718, 1994.
24. Akaboshi M, Watanabe J, Fujisawa T, Hattori M, Ohno E and Kuramoto H: Immunohistochemical expression of cdk2 and Ki-67 in human endometrial carcinoma. J Jpn Soc Clin Cytol 40: 121-127, 2001.
25. Kato N, Watanabe J, Jobo T, Nishimura Y, Fujisawa T, Kamata Y and Kuramoto H: Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol 129: 222-226, 2003.
26. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T and Kuramoto H: Expression of cyclin A in endometrial adenocarcinomas its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 128: 307-312, 2002.
27. Watanabe J, Sato H, Kanai T, Kamata Y, Jobo T, Hata H, Fujisawa T, Ohno E, Kameya T and Kuramoto H: Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - Correlation with proliferation and clinicopathological parameters. Br J Cancer 87: 81-85, 2002.
28. Fujisawa T, Watanabe J, Akaboshi M, Ohno E and Kuramoto H: Immunohistochemical study on VEGF expression in endometrial carcinoma-Comparison with p53 expression, angiogenesis, and tumor histologic grade. J Cancer Res Clin Oncol 127: 668-674, 2001.
29. Shiozawa T, Li S, Nakayama K, Nikaido T and Fujii S: Relationship between the expression of cyclins/cyclin-dependent kinases and sex-steroid receptors/Ki67 in normal human endometrial glands and stroma during the menstrual cycle. Mol Hum Reprod 2: 745-752, 1996.
30. Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R and Jones JG: Expression of COX-2, Ki-67, cyclin D1, and p21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 21: 147-154, 2002.
31. Ruhul Quddus M, Latkovich P, Castellani WJ, James Sung C, Steinhoff MM, Briggs RC and Miranda RN: Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med 126: 459-463, 2002.
32. Skomedal H, Kristensen GB, Nesland JM, Borresen-Dale AL, Trope C and Holm R: TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, cdk4, RB, MDM2, and EGFR in cancers of the uterine corpus. J Pathol 187: 556-562, 1999.
33. Tsuda H, Yamamoto K, Inoue T, Uchiyama I and Umesaki N: The role of p16-cyclin D/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer 82: 675-82, 2000.
34. RN: Cyclin D1 expression in high-grade endometrial carcinoma - Association with histologic subtype. Int J Gynecol Pathol 19: 329-334, 2000.
35. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, Hardisson D, Sarrio D, Prat J, Cigudosa JC, Matias-Guiu X, Palacios J: Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22: 6115-6118, 2003.
36. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV and Arnold A: Cyclin D1 (PRAD1) protein expression in breast cancer: Approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 8: 560-566, 1995.
37. Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, Musgrove EA, Nicholson RI and Sutherland RL: Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 2: 923-928, 1996.
38. Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW and Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. J Biol Chem 272: 10882-10894, 1997.
39. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R and Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415, 1997.
40. Salvesen HB, Iversen OE and Akslen LA: Prognostic significance of angiogenesis and ki-67, p53 and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17: 1382-1390, 1999.
41. Kallakury BV, Ambros RA, Hayner-Buchan AM, Sheehan CE, Malfetano JH and Ross JS: Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynacol Pathol 17: 320-326, 1998.
42. Geisler JP, Wiemann MC, Zhou Z, Miller GA and Geisler HE: p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 61: 245-248, 1996.
43. Maeda K, Chung Y, Kang S, Ogawa M, Onoda N, Nishiguchi Y, Ikehara T, Nakata B, Okuno M and Sowa M: Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 55: 145-151, 1998.
44. Naitoh H, Shibata J, Kawaguchi A, Kodama M and Hattori T: Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 146: 1161-1169, 1995.
45. Michalides R, Van veelen N, Hart A, Loftus B, Wientjens E and Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55: 975-978, 1995.